Emerging Trends in the Use of Topical Antifungal-Corticosteroid Combinations.

allylamines azoles ergosterol formulation fungi infection inflammation itch miconazole skin terbinafine

Journal

Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827

Informations de publication

Date de publication:
01 Aug 2022
Historique:
received: 11 07 2022
revised: 29 07 2022
accepted: 29 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

A broad range of topical antifungal formulations containing miconazole or terbinafine as actives are commonly used as efficacious choices for combating fungal skin infections. Their many benefits, owing to their specific mechanism of action, include their ability to target the site of infection, enhance treatment efficacy and reduce the risk of systemic side effects. Their proven efficacy, and positioning in the treatment of fungal skin infections, is enhanced by high patient compliance, especially when appropriate vehicles such as creams, ointments and gels are used. However, inflammation as a result of fungal infection can often impede treatment, especially when combined with pruritus (itch), an unpleasant sensation that elicits an urge to scratch. The scratching that occurs in response to pruritus frequently accelerates skin damage, ultimately aggravating and spreading the fungal infection. To help overcome this issue, a topical antifungal-corticosteroid combination consisting of miconazole or terbinafine and corticosteroids of varying potencies should be used. Due to their inherent benefits, these topical antifungal-corticosteroid combinations can concomitantly and competently attenuate inflammation, relieve pruritus and treat fungal infection.

Identifiants

pubmed: 36012800
pii: jof8080812
doi: 10.3390/jof8080812
pmc: PMC9409645
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Pharmaceutics. 2019 Dec 20;12(1):
pubmed: 31861803
Cells. 2019 Aug 01;8(8):
pubmed: 31374826
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001434
pubmed: 17636672
Future Microbiol. 2008 Jun;3(3):265-9
pubmed: 18505391
J Fungi (Basel). 2020 Feb 25;6(1):
pubmed: 32106450
Adv Exp Med Biol. 2016;892:327-349
pubmed: 26721281
Front Microbiol. 2020 Jul 28;11:1790
pubmed: 32849406
Australas J Dermatol. 2018 Aug;59(3):e168-e174
pubmed: 29411351
Front Microbiol. 2020 Jan 09;10:2993
pubmed: 31993032
Nat Rev Microbiol. 2018 Mar;16(3):143-155
pubmed: 29332945
An Bras Dermatol. 2013 Nov-Dec;88(6):937-44
pubmed: 24474103
Cell Host Microbe. 2017 Aug 9;22(2):156-165
pubmed: 28799901
Antimicrob Agents Chemother. 1998 May;42(5):1057-61
pubmed: 9593126
Clin Microbiol Rev. 1999 Jan;12(1):40-79
pubmed: 9880474
Dermatol Ther. 2017 Nov;30(6):
pubmed: 28940579
Infect Immun. 2021 Mar 17;89(4):
pubmed: 33468585
Mycopathologia. 2020 Apr;185(2):207-231
pubmed: 31894501
Int J Mol Sci. 2022 Mar 02;23(5):
pubmed: 35269898
Cochrane Database Syst Rev. 2014 Aug 04;(8):CD009992
pubmed: 25090020
Clin Microbiol Rev. 1999 Oct;12(4):501-17
pubmed: 10515900
Front Immunol. 2020 Dec 02;11:605644
pubmed: 33343578
Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):371-8
pubmed: 27279294
J Fungi (Basel). 2021 Nov 26;7(12):
pubmed: 34947085
Cold Spring Harb Perspect Med. 2014 Aug 01;4(8):
pubmed: 25085959
Microbiome. 2021 May 30;9(1):125
pubmed: 34053468
Curr Fungal Infect Rep. 2010 May 1;4(2):87-95
pubmed: 20574543
Front Microbiol. 2018 Jan 17;9:9
pubmed: 29387050
Cochrane Database Syst Rev. 2020 Jan 16;1:CD012093
pubmed: 31978269
Am Fam Physician. 2009 Jan 15;79(2):135-40
pubmed: 19178066
Dermatologica. 1976;153(4):228-35
pubmed: 797593
J Investig Allergol Clin Immunol. 2018 Dec;28(6):379-391
pubmed: 30004024
Nutrients. 2021 Jun 15;13(6):
pubmed: 34203999
Aust J Gen Pract. 2021 Sep;50(9):651-655
pubmed: 34462770
Prim Care. 2015 Dec;42(4):501-16
pubmed: 26612371
J Cutan Med Surg. 2018 Mar/Apr;22(2):207-212
pubmed: 29137492
Expert Rev Clin Pharmacol. 2017 Feb;10(2):225-237
pubmed: 27868472
Molecules. 2021 Feb 19;26(4):
pubmed: 33669627
Indian Dermatol Online J. 2014 Oct;5(4):416-25
pubmed: 25396122
Aust J Gen Pract. 2019 Oct;48(10):706-711
pubmed: 31569324
Evolution. 2012 Sep;66(9):2961-8
pubmed: 22946816
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769105
Arch Dermatol. 1985 Jan;121(1):63-7
pubmed: 3881088
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013709
Exp Dermatol. 2016 Feb;25(2):92-8
pubmed: 26284579
Cell. 2016 May 5;165(4):771-2
pubmed: 27153488
Cell Host Microbe. 2020 Aug 12;28(2):190-200
pubmed: 32791112
J Fungi (Basel). 2018 Aug 20;4(3):
pubmed: 30127244
Indian J Pharmacol. 2021 Jan-Feb;53(1):82-84
pubmed: 33976006
mBio. 2019 Jul 2;10(4):
pubmed: 31266865
Biol Rev Camb Philos Soc. 2020 Oct;95(5):1198-1232
pubmed: 32301582
Indian J Dermatol. 2012 Jul;57(4):251-9
pubmed: 22837556
Expert Rev Anti Infect Ther. 2006 Apr;4(2):171-5
pubmed: 16597199
Drugs. 2001;61 Suppl 1:13-25
pubmed: 11219547
Mycoses. 2015 Jun;58 Suppl 2:2-13
pubmed: 26033251
J Appl Microbiol. 2016 Dec;121(6):1498-1510
pubmed: 27667746
Indian J Dermatol. 2017 May-Jun;62(3):227-236
pubmed: 28584364
Medicines (Basel). 2019 Jul 18;6(3):
pubmed: 31323753
Pharmaceutics. 2021 Sep 13;13(9):
pubmed: 34575532
Front Microbiol. 2018 Jul 03;9:1351
pubmed: 30018595
Microorganisms. 2021 Mar 05;9(3):
pubmed: 33808031
Pharmaceutics. 2021 Nov 26;13(12):
pubmed: 34959294
Clin Cosmet Investig Dermatol. 2009 Apr 21;2:49-63
pubmed: 21436968
Med J Aust. 2007 Oct 1;187(7):404-9
pubmed: 17908006
Skin Pharmacol Physiol. 2021;34(3):146-161
pubmed: 33780956
Drugs. 1992 Feb;43(2):259-84
pubmed: 1372222
Acta Derm Venereol. 2010 Jul;90(4):368-73
pubmed: 20574601
Annu Rev Microbiol. 2015;69:71-92
pubmed: 26488273
Indian Dermatol Online J. 2018 May-Jun;9(3):149-158
pubmed: 29854633
Mycoses. 2016 Jun;59(6):365-73
pubmed: 26916648
Med Mycol. 2019 Jan 1;57(1):13-22
pubmed: 29361043
Australas J Dermatol. 2015 May;56(2):e30-4
pubmed: 24372079
Pharmaceutics. 2018 Jun 14;10(2):
pubmed: 29899219
J Fungi (Basel). 2021 Dec 31;8(1):
pubmed: 35049979
PLoS Pathog. 2010 Jun 03;6(6):e1000939
pubmed: 20532216
JAMA Dermatol. 2014 Jan;150(1):47-50
pubmed: 24226568
Australas J Dermatol. 2015 Nov;56(4):241-51
pubmed: 25752907

Auteurs

Dalibor Mijaljica (D)

Department of Scientific Affairs, Ego Pharmaceuticals Pty Ltd., 21-31 Malcolm Road, Braeside, VIC 3195, Australia.

Fabrizio Spada (F)

Department of Scientific Affairs, Ego Pharmaceuticals Pty Ltd., 21-31 Malcolm Road, Braeside, VIC 3195, Australia.

Ian P Harrison (IP)

Department of Scientific Affairs, Ego Pharmaceuticals Pty Ltd., 21-31 Malcolm Road, Braeside, VIC 3195, Australia.

Classifications MeSH